(S)-2-(2-aminothiazol-4-yl)-N-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)propanamide | 1190389-17-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-2-(2-aminothiazol-4-yl)-N-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)propanamide
• 英文别名: (2S)-2-(2-amino-1,3-thiazol-4-yl)-N-[4-[[(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]propanamide
• CAS: 1190389-17-3
• 化学式: C₂₄H₂₈N₄O₂S
• 分子量: 436.578
• InChiKey: OARXYWDYXBWAPJ-CNWYBHPASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  129
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-溴-2-甲基-3-氧代丁酸乙酯 在 4-二甲氨基吡啶 、 水 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氟乙酸 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 (S)-2-(2-aminothiazol-4-yl)-N-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)propanamide
  参考文献：
  名称：

  Design, Synthesis, and Evaluation of Conformationally Restricted Acetanilides as Potent and Selective β₃Adrenergic Receptor Agonists for the Treatment of Overactive Bladder

  摘要：

  A series of conformationally restricted acetanilides were synthesized and evaluated as beta(3)-adrenergic receptor agonists (beta(3)-AR) for the treatment of overactive bladder (OAB). Optimization studies identified a five-membered ring as the preferred conformational lock of the acetanilide. Further optimization of both the aromatic and thiazole regions led to compounds such as 19 and 29, which have a good balance of potency and selectivity. These compounds have significantly reduced intrinsic clearance compared to our initial series of pyridylethanolamine beta(3)-AR agonists and thus have improved unbound drug exposures. Both analogues demonstrated dose dependent beta(3)-AR mediated responses in a rat bladder hyperactivity model.

  DOI：

  10.1021/jm4017224

文献信息

• [EN] HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS<br/>[FR] HYDROXYMÉTHYL PYRROLIDINES EN TANT QU'AGONISTES DE RÉCEPTEUR BÊTA 3 ADRÉNERGIQUE
  申请人：MERCK & CO INC

  公开号：WO2009124167A1

  公开（公告）日：2009-10-08

  The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了化合物(I)、其制药组合物以及使用它们治疗或预防由β3肾上腺素能受体激活介导的疾病的方法。
• US8653260B2
  申请人：——

  公开号：US8653260B2

  公开（公告）日：2014-02-18
• [EN] HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS<br/>[FR] HYDROXYMÉTHYL PYRROLIDINES EN TANT QU'AGONISTES DES RÉCEPTEURS ADRÉNERGIQUES BÊTA 3
  申请人：MERCK & CO INC

  公开号：WO2009124166A1

  公开（公告）日：2009-10-08

  The present invention provides compounds of Formula (Ia), pharmaceutical compositions thereof, and methods of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.
• Design, Synthesis, and Evaluation of Conformationally Restricted Acetanilides as Potent and Selective β₃Adrenergic Receptor Agonists for the Treatment of Overactive Bladder
  作者：Christopher R. Moyes、Richard Berger、Stephen D. Goble、Bart Harper、Dong-Ming Shen、Liping Wang、Alka Bansal、Patricia N. Brown、Airu S. Chen、Karen H. Dingley、Jerry Di Salvo、Aileen Fitzmaurice、Loise N. Gichuru、Amanda L. Hurley、Nina Jochnowitz、Randall R. Miller、Shruty Mistry、Hiroshi Nagabukuro、Gino M. Salituro、Anthony Sanfiz、Andra S. Stevenson、Katherine Villa、Beata Zamlynny、Mary Struthers、Ann E. Weber、Scott D. Edmondson

  DOI：10.1021/jm4017224

  日期：2014.2.27

  A series of conformationally restricted acetanilides were synthesized and evaluated as beta(3)-adrenergic receptor agonists (beta(3)-AR) for the treatment of overactive bladder (OAB). Optimization studies identified a five-membered ring as the preferred conformational lock of the acetanilide. Further optimization of both the aromatic and thiazole regions led to compounds such as 19 and 29, which have a good balance of potency and selectivity. These compounds have significantly reduced intrinsic clearance compared to our initial series of pyridylethanolamine beta(3)-AR agonists and thus have improved unbound drug exposures. Both analogues demonstrated dose dependent beta(3)-AR mediated responses in a rat bladder hyperactivity model.